Tatyana Kisina, MD
Pain Medicine · Brooklyn, NYNPI 1245265586
Payments from drug & device makers
Across 221 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novartis$658
- AbbVie$614
- Sumitomo Pharma America, Inc.$468
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$434
- Merck$260
- plus $1K from 17 others
What the payments were for
- Food & beverage$5,206100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 48 | $1,303 |
| Novartis | 27 | $658 |
| AbbVie | 28 | $614 |
| Sumitomo Pharma America, Inc. | 30 | $468 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $434 |
| Merck | 15 | $260 |
| Novo Nordisk | 2 | $239 |
| GSK | 10 | $237 |
| AstraZeneca | 7 | $180 |
| Boehringer Ingelheim | 7 | $170 |
| Scilex Pharmaceuticals Inc. | 1 | $150 |
| Lilly USA, LLC | 6 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Almatica Pharma LLC | 2 | $57 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,206 in reported general payments places this provider in the 75th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxepin Hcl | 100 | $26,072 |
| Lidocaine Hcl ViscousLidocaine Hcl | 85 | $5,298 |
| Celecoxib | 72 | $5,116 |
| Diclofenac Potassium | 39 | $3,497 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Brooklyn
- Gary SchwartzBrooklyn$756K
- David RosenblumBrooklyn$105K
- Jacob RauchwergerBrooklyn$41K
- Thomas del GuercioBrooklyn$22K
- Jason KreinerBrooklyn$18K
- Roman ShulkinBrooklyn$15K
- Amitabh GulatiNew York$627K
- William CaldwellStony Brook$550K
- Brian DurkinPort Jefferson$459K
- Grace FordeNew Hyde Park$398K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.